Drugs / PF-06425090
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03090191 | Mar 2017 → Dec 2021 | Clostridium difficile colitis | Pfizer | Completed | Missed primary |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2022-03-01 | Pfizer | Results Phase 3 CLOVER Trial for Pfizer’s Investigational Clostridioides Difficile Vaccine Indicates Strong Potential Effect in Reducing Duration and Severity of Disease Based on Secondary Endpoints pfizer.com ↗
Pfizer Inc. (NYSE:PFE) today announced results from the CLOVER trial ( CLO stridium difficile V accine E fficacy T R ial), a pivotal Phase 3 study evaluating its Clostridioides difficile ( C. difficile ) vaccine candidate (PF-06425090) in the prevention of C. difficile infection (CDI). |
| 2017-01-26 | Pfizer | Results Pfizer Announces Positive Top-Line Results from Phase 2 Study of Investigational Clostridium difficile Vaccine for the Prevention of C. difficile Infection pfizer.com ↗
Pfizer Inc. (NYSE:PFE) announced today that the Phase 2 study evaluating the Company’s Clostridium difficile (C. difficile) vaccine candidate, PF-06425090, provided positive data, based on a pre-planned interim analysis. |
All press releases naming this drug 2 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-06425090 | “We assessed the detoxified toxin-A/B PF-06425090 vaccine for primary CDI prevention.” PMID 39180325 ↗ Dec 2024 |
| Modality | Vaccine | “We assessed the detoxified toxin-A/B PF-06425090 vaccine for primary CDI prevention.” PMID 39180325 ↗ Dec 2024 |